News archive

Latest news

23 May 2022

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

26 Apr 2022

Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks

14 Apr 2022

Idorsia holds its Annual General Meeting of Shareholders

03 Mar 2022

Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders

25 Feb 2022

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

08 Feb 2022

Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025

24 Jan 2022

Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development

20 Jan 2022

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

10 Jan 2022

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

13 Dec 2021

Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

01 Nov 2021

Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus

27 Oct 2021

Johnson & Johnson partially converts its convertible loan

26 Oct 2021

Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway

11 Oct 2021

Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

29 Jul 2021

Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd

28 Jul 2021

Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company

27 Jul 2021

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company

28 Jun 2021

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

25 May 2021

European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

12 May 2021

Idorsia holds its Annual General Meeting of Shareholders

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.